Turcotte Lucie M, Liu Qi, Yasui Yutaka, Arnold Michael A, Hammond Sue, Howell Rebecca M, Smith Susan A, Weathers Rita E, Henderson Tara O, Gibson Todd M, Leisenring Wendy, Armstrong Gregory T, Robison Leslie L, Neglia Joseph P
University of Minnesota Medical School, Minneapolis.
School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
JAMA. 2017 Feb 28;317(8):814-824. doi: 10.1001/jama.2017.0693.
Cancer treatments are associated with subsequent neoplasms in survivors of childhood cancer. It is unknown whether temporal changes in therapy are associated with changes in subsequent neoplasm risk.
To quantify the association between temporal changes in treatment dosing and subsequent neoplasm risk.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective, multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United States and Canada between 1970-1999, with follow-up through December 2015.
Radiation and chemotherapy dose changes over time.
Subsequent neoplasm 15-year cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancies, compared by treatment decade. Multivariable models assessed relative rates (RRs) of subsequent neoplasms by 5-year increments, adjusting for demographic and clinical characteristics. Mediation analyses assessed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable modifications.
Among 23 603 survivors of childhood cancer (mean age at diagnosis, 7.7 years; 46% female) the most common initial diagnoses were acute lymphoblastic leukemia, Hodgkin lymphoma, and astrocytoma. During a mean follow-up of 20.5 years (374 638 person-years at risk), 1639 survivors experienced 3115 subsequent neoplasms, including 1026 malignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers. The most common subsequent malignancies were breast and thyroid cancers. Proportions of individuals receiving radiation decreased (77% for 1970s vs 33% for 1990s), as did median dose (30 Gy [interquartile range, 24-44] for 1970s vs 26 Gy [interquartile range, 18-45] for 1990s). Fifteen-year cumulative incidence of subsequent malignancies decreased by decade of diagnosis (2.1% [95% CI, 1.7%-2.4%] for 1970s, 1.7% [95% CI, 1.5%-2.0%] for 1980s, 1.3% [95% CI, 1.1%-1.5%] for 1990s). Reference absolute rates per 1000 person-years were 1.12 (95% CI, 0.84-1.57) for subsequent malignancies, 0.16 (95% CI, 0.06-0.41) for meningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years). Standardized incidence ratios declined for subsequent malignancies over treatment decades, with advancing attained age. Relative rates declined with each 5-year increment for subsequent malignancies (RR, 0.87 [95% CI, 0.82-0.93]; P < .001), meningiomas (RR, 0.85 [95% CI, 0.75-0.97]; P = .03), and nonmelanoma skin cancers (RR, 0.75 [95% CI, 0.67-0.84]; P < .001). Radiation dose changes were associated with reduced risk for subsequent malignancies, meningiomas, and nonmelanoma skin cancers.
Among survivors of childhood cancer, the risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s, although the risk was lower compared with those diagnosed in the 1970s. This lower risk was associated with reduction in therapeutic radiation dose.
癌症治疗与儿童癌症幸存者后续发生的肿瘤有关。治疗方法随时间的变化是否与后续肿瘤风险的变化相关尚不清楚。
量化治疗剂量随时间的变化与后续肿瘤风险之间的关联。
设计、设置和参与者:对1970年至1999年间在美国和加拿大的儿科三级医院诊断出的21岁前患癌的5年癌症幸存者进行回顾性、多中心队列研究,随访至2015年12月。
放疗和化疗剂量随时间的变化。
按治疗年代比较后续肿瘤的15年累积发病率、累积负担以及后续恶性肿瘤的标准化发病率比。多变量模型评估了按5年增量计算的后续肿瘤的相对发生率(RR),并对人口统计学和临床特征进行了调整。中介分析评估了后续肿瘤发生率随时间的变化是否由治疗变量的改变介导。
在23603名儿童癌症幸存者中(诊断时的平均年龄为7.7岁;46%为女性),最常见的初始诊断为急性淋巴细胞白血病、霍奇金淋巴瘤和星形细胞瘤。在平均20.5年的随访期(374638人年的风险期)内,1639名幸存者发生了3115例后续肿瘤,包括1026例恶性肿瘤、233例良性脑膜瘤和1856例非黑色素瘤皮肤癌。最常见的后续恶性肿瘤是乳腺癌和甲状腺癌。接受放疗的个体比例下降(20世纪70年代为77%,20世纪90年代为33%),中位剂量也下降(20世纪70年代为30 Gy[四分位间距,24 - 44],20世纪90年代为26 Gy[四分位间距,18 - 45])。后续恶性肿瘤的15年累积发病率随诊断年代的推移而下降(20世纪70年代为2.1%[95%CI,1.7% - 2.4%],20世纪80年代为1.7%[95%CI,1.5% - 2.0%],20世纪90年代为1.3%[95%CI,1.1% - 1.5%])。具有参考特征(未接受化疗、脾切除术或放疗;男性;达到28岁)的幸存者每1000人年的后续恶性肿瘤参考绝对发生率为1.12(95%CI,0.84 - 1.57),脑膜瘤为0.16(95%CI,0.06 - 0.41),非黑色素瘤皮肤癌为1.71(95%CI,0.88 - 3.33)。随着治疗年代的推进以及达到年龄的增加,后续恶性肿瘤的标准化发病率比下降。后续恶性肿瘤(RR,0.87[95%CI,0.82 - 0.93];P <.001)、脑膜瘤(RR,0.85[95%CI,0.75 - 0.97];P = 0.03)和非黑色素瘤皮肤癌(RR,0.75[95%CI,0.67 - 0.84];P <.001)的相对发生率随着每5年的增量而下降。放疗剂量的变化与后续恶性肿瘤、脑膜瘤和非黑色素瘤皮肤癌风险的降低相关。
在儿童癌症幸存者中,20世纪90年代诊断出的患者在初始癌症诊断后15年发生后续恶性肿瘤的风险仍然增加,尽管与20世纪70年代诊断出的患者相比风险较低。这种较低的风险与治疗性放疗剂量的降低有关。